Featured Research

from universities, journals, and other organizations

Alzheimer's Drug Reverses Cognitive Decline Over 12 Month Period In Early Human Testing

Date:
July 18, 2008
Source:
Baylor College of Medicine
Summary:
A drug once approved as an antihistamine in Russia improved thinking processes and ability to function in patients with Alzheimer's disease in a new study. Dimebon is the first drug tested for Alzheimer's disease that demonstrated continued improvement in patients over a 12 month period.

PET scan of Alzheimer's disease brain.
Credit: National Institute on Aging, NIH

A drug once approved as an antihistamine in Russia improved thinking processes and ability to function in patients with Alzheimer's disease in a study conducted there, said an expert at Baylor College of Medicine in Houston. The findings are published in the journal The Lancet.

Related Articles


"More research is needed, but we are encouraged by the effect the drug Dimebon had on Alzheimer's patients" said Dr. Rachelle Doody, professor of neurology at BCM and lead author of the study.

In the study, the authors noted that Dimebon is the first drug for Alzheimer's disease that demonstrated continued improvement in patients over a 12 month period. Other approved drugs do not have this effect.

Half of the 183 patients in the Russian study received Dimebon; the other half were given a placebo or an inactive pill. Clinicians at the study sites then monitored the patients' progress over the next year on five different outcomes. All of those in the study had mild to moderate Alzheimer's disease.

"What we saw in the clinical trial is that people on the medication continued to improve over time," Doody said. "Those on placebo continued to decline."

Researchers believe the medication works by stabilizing mitochondria, the cellular components that produce energy, and possibly by inhibiting brain cell death. Researchers evaluated patients' thinking and memory ability, overall function, psychiatric and behavioral symptoms, and ability to perform daily activities.

"Usually at this point in a drug's development, we are happy to see improvement in one of the outcome measures," Doody said. "We saw improvement in all five."

Some participants complained of occasional dry mouth, but no one opted out of the study because of the side effects.

"As we continue research, we hope to replicate these results," Doody said. "My belief is that this drug will turn out to be useful for Alzheimer's disease, regardless of the stage of the disease."

Doody said this is only the first study looking into the effects of Dimebon on Alzheimer's disease. She also noted that it involved only a relatively small population from one specific region of the world. The ongoing Phase 3 study will include several international locations including the United States.

Other researchers who contributed to this study include: Dr. Svetlana I. Gavrilova, Russian Academy of Medical Sciences, Moscow, Russia; Dr. Mary Sano, Mount Sinai School of Medicine, New York City, NY; Dr. Ronald G. Thomas, University of California, San Diego, La Jolla, CA; Dr. Paul S. Aisen, formerly with Georgetown University School of Medicine, Washington, DC and now at the University of California, San Diego; ; Dr. Sergey O. Bachurin, Russian Academy of Sciences, Institute of Physiologically Active Compounds, Chernogolovka, Russia; Drs. Lynn Seely and David Hung, Medivation, Inc., San Francisco, CA.

Funding for this study came from Medivation, Inc., the company developing the drug worldwide. Doody is also a member of the Scientific and Clinical Advisory board for Medivation, Inc.


Story Source:

The above story is based on materials provided by Baylor College of Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Dimebon for Alzheimer's disease. The Lancet, July 18, 2008 [link]

Cite This Page:

Baylor College of Medicine. "Alzheimer's Drug Reverses Cognitive Decline Over 12 Month Period In Early Human Testing." ScienceDaily. ScienceDaily, 18 July 2008. <www.sciencedaily.com/releases/2008/07/080717193029.htm>.
Baylor College of Medicine. (2008, July 18). Alzheimer's Drug Reverses Cognitive Decline Over 12 Month Period In Early Human Testing. ScienceDaily. Retrieved November 26, 2014 from www.sciencedaily.com/releases/2008/07/080717193029.htm
Baylor College of Medicine. "Alzheimer's Drug Reverses Cognitive Decline Over 12 Month Period In Early Human Testing." ScienceDaily. www.sciencedaily.com/releases/2008/07/080717193029.htm (accessed November 26, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, November 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) — The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) — Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com
Madagascar Working to Contain Plague Outbreak

Madagascar Working to Contain Plague Outbreak

AFP (Nov. 24, 2014) — Madagascar said Monday it is trying to contain an outbreak of plague -- similar to the Black Death that swept Medieval Europe -- that has killed 40 people and is spreading to the capital Antananarivo. Duration: 00:42 Video provided by AFP
Powered by NewsLook.com
Are Female Bosses More Likely To Be Depressed?

Are Female Bosses More Likely To Be Depressed?

Newsy (Nov. 24, 2014) — A new study links greater authority with increased depressive symptoms among women in the workplace. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins